This clinical trial examines a nutritional and drug intervention for managing loss of appetite in cancer patients. Loss of appetite is a common symptom and can cause distress which impacts patients and caregivers. Nutrition intervention may provide beneficial outcomes in terms of positive impact on nutrition status, physical function, quality of life, weight maintenance, and overall survival in cancer patients. This trial may help decrease the suffering and distress associated with eating during cancer treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT04155008.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To establish the feasibility of implementing an algorithm for nutrition interventions in our cancer center.
SECONDARY OBJECTIVE:
I. To assess associations between appetite scores and general quality of life measures in cancer patients.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I: Patients with fair-good appetite (Council of Nutrition Appetite Questionnaire score [CNAQ] score > 24) receive nutrition intervention. Patient also completion questionnaires biweekly.
GROUP II: Patients with poor-fair appetite (CNAQ score < 24) receive nutrition intervention. Patients also receive dexamethasone orally (PO) once daily (QD) in the morning; medical marijuana (if history of marijuana use) or dronabinol; or mirtazapine PO QD at bedtime in the absence of unacceptable toxicity. Patients complete questionnaires weekly.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationMontefiore Medical Center-Weiler Hospital
Principal InvestigatorJustin Tang
